Diabetology & Metabolic Syndrome最新文献

{"title":"Hypoglycemic agents and bone health; an umbrella systematic review of the clinical trials' meta-analysis studies.","authors":"Pouria Khashayar, Farid Farahani Rad, Ozra Tabatabaei-Malazy, Sara MohammadHosseinzadeh Golabchi, Patricia Khashayar, Mehdi Mohammadi, Sholeh Ebrahimpour, Bagher Larijani","doi":"10.1186/s13098-024-01518-2","DOIUrl":"10.1186/s13098-024-01518-2","url":null,"abstract":"<p><strong>Background: </strong>No clear consensus exists regarding the safest anti-diabetic drugs with the least adverse events on bone health. This umbrella systematic review therefore aims to assess the published meta-analysis studies of randomized controlled trials (RCTs) conducted in this field.</p><p><strong>Methods: </strong>All relevant meta-analysis studies of RCTs assessing the effects of anti-diabetic agents on bone health in patients with diabetes mellitus (DM) were collected in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). English articles published until 15 March 2023 were collected through the search of Cochrane Library, Scopus, ISI Web of Sciences, PubMed, and Embase using the terms \"Diabetes mellitus\", \"anti-diabetic drugs\", \"Bone biomarker\", \"Bone fracture, \"Bone mineral density\" and their equivalents. The methodological and evidence quality assessments were performed for all included studies.</p><p><strong>Results: </strong>From among 2220 potentially eligible studies, 71 meta-analyses on diabetic patients were included. Sodium-glucose cotransporter-2 inhibitors (SGLT-is) showed no or equivalent effect on the risk of fracture. Dipeptidyl peptidase-4 inhibitors (DPP-4is) and Glucagon-like peptide-1 receptor agonists (GLP-1Ras) were reported to have controversial effects on bone fracture, with some RCTs pointing out the bone protective effects of certain members of these two medication classes. Thiazolidinediones (TZDs) were linked with increased fracture risk as well as higher concentrations of C-terminal telopeptide of type I collagen (CTx), a bone resorption marker.</p><p><strong>Conclusion: </strong>The present systematic umbrella review observed varied results on the association between the use of anti-diabetic drugs and DM-related fracture risk. The clinical efficacy of various anti-diabetic drugs, therefore, should be weighed against their risks and benefits in each patient.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"310"},"PeriodicalIF":3.4,"publicationDate":"2024-12-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11665059/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of liraglutide on abdominal fat distribution and glucose metabolism in Chinese subjects with obesity.","authors":"Mengyang Du, Jiang Yue, Yicheng Qi, Shengyun He, Xiaobing Lu, Minglan Yang, Lihua Wang, Qing Lu, Jing Ma","doi":"10.1186/s13098-024-01540-4","DOIUrl":"10.1186/s13098-024-01540-4","url":null,"abstract":"<p><strong>Aims: </strong>To observe the effects of liraglutide on abdominal fat distribution in Chinese subjects with obesity in 12 weeks, and further to explore the correlation between abdominal fat content and glucose metabolism after monotherapy.</p><p><strong>Methods: </strong>This study recruited 71 obese subjects. All the subjects have received liraglutide monotherapy (0.6 mg-1.8 mg/d) for 12 weeks. Clinical assessment, laboratory assays and magnetic resonance imaging (MRI) examination were accessed at baseline and after 12 weeks treatment. MRI was applied to measure abdominal fat distribution, calculated by proton-density fat fraction (PDFF).</p><p><strong>Results: </strong>After 12 weeks of liraglutide monotherapy, body weight in the obese participants decreased significantly (P < 0.001). Fasting blood glucose (FBG) levels, 2 h post-load blood glucose (2hPBG) levels, and glycosylated hemoglobin (HbA1c) were remarkably improved after liraglutide monotherapy (all P < 0.001). Subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) were significantly reduced after liraglutide monotheraphy (both P < 0.001). There was a notable reduction in liver fat content (LFC) after liraglutide monotherapy (P < 0.001). In the further analysis, LFC was greater in obese subjects with impaired glucose regulation (IGR) at baseline compared to those with normal glucose tolerance (NGT) (P = 0.002). The LFC reduction in IGR group was significantly greater than those in NGT group after liraglutide treatment (P < 0.001). Pearson correlation analysis showed that reduction of LFC was significantly correlated with improvement of FBG (r = 0.587, P < 0.001) and HbA1c (r = 0.607, P < 0.001) in obese patients.</p><p><strong>Conclusion: </strong>LFC was significantly reduced after liraglutide monotherapy for 12 weeks in subjects with obesity. The LFC reduction is likely to be associated with IGR remission in obese subjects.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"307"},"PeriodicalIF":3.4,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11660634/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of frequency changes in CD8⁺ regulatory T cell subsets in peripheral blood of individuals with type 1 diabetes.","authors":"Shu Chen, Gaoqiang Meng, Xing Wang, Hemin Jiang, Min Shen, Xueqin Wang, Chunhua Wang","doi":"10.1186/s13098-024-01549-9","DOIUrl":"10.1186/s13098-024-01549-9","url":null,"abstract":"<p><strong>Background: </strong>This study aims to examine the alterations and clinical significance of CD8⁺ regulatory T cell subsets in the peripheral blood of individuals with type 1 diabetes mellitus (T1DM).</p><p><strong>Methods: </strong>From January 2020 to December 2023, a study was conducted involving 40 individuals with T1DM, who visited the Department of Endocrinology at the First Affiliated Hospital of Nanjing Medical University (T1DM group). For comparison, 40 healthy individuals who underwent routine physical examinations at the same hospital during this period were selected as the control group. Peripheral blood mononuclear cells were isolated, and CD8⁺ T cells were labeled with CD3, CD25 and FoxP3 to analyze their subset frequencies using flow cytometry. The study examined differences in subset frequencies between the two groups and explored correlations between subset frequency, disease duration, and age of onset.</p><p><strong>Results: </strong>The frequencies of CD8⁺ CD25⁺, CD8⁺ FoxP3⁺, CD8⁺ CD25⁺ CD3⁺ and CD8⁺ FoxP3⁺ CD3⁺ subsets in peripheral blood mononuclear cells did not significantly differ between the healthy control group and the T1DM group (P > 0.05). In the T1DM group, the expression level of CD25 on CD8⁺ T cells showed no correlation with the age of onset or disease duration, and FoxP3 levels were also unrelated to the age of onset, with no statistical differences (P > 0.05). However, within the T1DM group, FoxP3 levels progressively decreased with longer disease duration, demonstrating a statistically significant negative correlation (Pearson r = -0.331, P < 0.05). In the T1DM group, the level of CD3⁺ CD8⁺ T cells expressed CD25, and there was no correlation between Foxp 3 level and age of onset, not statistically significant (P > 0.05), but the level of Foxp 3 in the T1DM group decreased with the duration of the disease, (Pearson r= - 0.363, P < 0.05).</p><p><strong>Conclusion: </strong>The levels of CD8⁺FoxP3⁺ regulatory T cells in peripheral blood mononuclear cells of patients with T1DM show a significant correlation with disease duration, suggesting that these cells may play a critical role in the progression of T1DM.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"305"},"PeriodicalIF":3.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11656918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predictive properties of novel anthropometric and biochemical indexes for prediction of cardiovascular risk.","authors":"Amin Mansoori, Maryam Allahyari, Mobina Sadat Mirvahabi, Davoud Tanbakuchi, Sahar Ghoflchi, Elahe Derakhshan-Nezhad, Farnoosh Azarian, Gordon Ferns, Habibollah Esmaily, Majid Ghayour-Mobarhan","doi":"10.1186/s13098-024-01516-4","DOIUrl":"10.1186/s13098-024-01516-4","url":null,"abstract":"<p><strong>Objective: </strong>Our aim was to examine the correlation between CVDs and various anthropometric and biochemical indices in the Iranian population.</p><p><strong>Methods: </strong>9704 healthy individuals without CVD aged 35-65 were enrolled in our study. The anthropometric indices including Body Adiposity Index (BAI), Abdominal Volume Index (AVI), Body Roundness Index (BRI), Waist to Hip Ratio (WHR), Weight-adjusted Waist Index (WWI), Conicity Index (C-Index), A Body Shape Index (ABSI), Waist to Height Ratio (WHtR), Body Surface Area (BSA), Body Mass Index (BMI), Lipid Accumulation Product (LAP) and Visceral Adiposity Index (VAI) were calculated. The biochemical indices including Cardiac Risk Ratio (CRR), Atherogenic Index of Plasma (AIP), Triglycerides-Glucose Index (TyG), Cardiac Risk Index (CRI), Atherogenic Coefficient (AC), and high-sensitivity C-Reactive Protein (hs-CRP) were investigated. The association of the above indices with CVD was analyzed using logistic regression (LR) and the decision tree (DT) models.</p><p><strong>Results: </strong>The LR showed age, hs-CRP, AIP, AVI, LAP, and TyG had significant associations with CVDs in men (p-value < 0.002). Also, age, hs-CRP, LAP, TyG, BRI, VAI, and CRR had significant associations with CVDs in women (p-value < 0.002). The DT showed 95% of men with age > = 48, AIP > = 0.94, TyG > = 9.71, and AVI > = 14.24 had CVDs. Also, 97% of women with age > = 54, TyG > = 8.33, and hs-CRP > = 36.69 had CVDs.</p><p><strong>Conclusion: </strong>Age, TyG, AIP, AVI, hs-CRP and LAP were the best predictors of CVD in men. Moreover, age, TyG, hs-CRP and BAI were the best indicators of CVD in women.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"304"},"PeriodicalIF":3.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657368/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supaglutide alleviates hepatic steatosis in monkeys with spontaneous MASH.","authors":"Qinghua Wang, Yue Zhou, Yunzhi Ni, Zhihong Wang, Yan-Ru Lou, Zunyuan Yang, Li Gong, Yinan Liang, Wen Zeng, Gerald J Prud'homme","doi":"10.1186/s13098-024-01513-7","DOIUrl":"10.1186/s13098-024-01513-7","url":null,"abstract":"<p><strong>Background: </strong>Glucagon-like peptide 1 (GLP-1) is an incretin hormone and plays an important role in regulating glucose homeostasis. GLP-1 has a short half-life due to degrading enzyme dipeptidyl peptidase-IV and rapid kidney clearance, which limits its clinical application as a therapeutic agent. We demonstrated previously that supaglutide, a novel long-acting GLP-1 analog, exerted hypoglycemic, hypolipidemic, and weight loss effects in type 2 diabetic db/db mice, DIO mice, and diabetic monkeys. In the present study, we investigated supaglutide's therapeutic efficacy in rhesus monkeys with spontaneous metabolic dysfunction-associated steatohepatitis (MASH).</p><p><strong>Methods: </strong>15 rhesus monkeys with biopsy-confirmed MASH were divided into three groups, receiving supaglutide 50 µg/kg, supaglutide 150 µg/kg, and placebo, respectively, by weekly subcutaneous injection for 3 months. Liver fat content quantified by magnetic resonance imaging-estimated proton density fat fraction (MRI-PDFF), liver pathology, and metabolic parameters were assessed.</p><p><strong>Results: </strong>We found that once-weekly subcutaneous injections of supaglutide for 3 months significantly reduced hepatic fat accumulation, with a 40% percentage decrease in MRI-PDFF from baseline (P < 0.001 vs. Placebo). Treatment with supaglutide alleviated hepatic histological steatosis (nonalcoholic fatty liver disease activity score P < 0.001 vs. Placebo) without worsening of fibrosis, as assessed by ultrasound-guided liver biopsy. Supaglutide concomitantly ameliorated liver injury exemplified by a lowering tendency of hepatic alanine aminotransferase levels. Supaglutide also decreased body weight in a dose-dependent fashion accompanied by decreased food intake, improved lipid profile and glycemic control.</p><p><strong>Conclusions: </strong>Supaglutide exerts beneficial effects on hepatic and metabolic outcomes in spontaneous MASH monkeys.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"303"},"PeriodicalIF":3.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11658388/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of glycemic treatment and blood glucose monitoring on outcomes in patients with acute ischemic stroke without prior diabetes: a longitudinal cohort study.","authors":"Hsi-Hsing Yang, Wu-Chien Chien, Jen-Jiuan Liaw, Chia-Chen Yang, Chi-Hsiang Chung, Shi-Hao Huang, Yao-Ching Huang, Bing-Long Wang, Ren-Jei Chung, Peng-Ciao Chen, Ting-Ti Lin, Pi-Ching Yu, Yu-Ju Chen","doi":"10.1186/s13098-024-01542-2","DOIUrl":"10.1186/s13098-024-01542-2","url":null,"abstract":"<p><strong>Objectives: </strong>To explore the short- and long-term effects of glycemic management-through glycemic treatment and blood glucose monitoring (BGM)-on stroke recurrence and mortality specifically in patients experiencing a first-ever ischemic stroke (FIS) with hyperglycemia (FISHG) who have not previously been diagnosed with diabetes mellitus (DM).</p><p><strong>Methods: </strong>We gathered data on patients who were registered on Taiwan's National Health Insurance Research Database from 2000 to 2015. We one-fold propensity-score-matched (by sex, age, and index date) 207,054 patients into 3 cohorts: those with FIS (1) without hyperglycemia, (2) hyperglycemia without glycemic treatment, and (3) hyperglycemia with glycemic treatment. We used Cox proportional hazard regression to evaluate the short- (within 1 year after FIS) and long-term (9.3 ± 8.6 years after FIS) prognostic effects of glycemic management on stroke recurrence and mortality of FISHG.</p><p><strong>Results: </strong>Stroke recurrence and mortality were significantly more likely in the patients with FISHG than their counterparts without hyperglycemia (p < 0.05). Under glycemic treatment, patients with FISHG demonstrated lower risk of mortality at every follow-up than those without (p < 0.001) but were not less likely to have stroke recurrence (p > 0.05). Integrating BGM with glycemic treatment in the FISHG cohort significantly reduced the risk of stroke recurrence compared to patients receiving only glycemic treatment at 1-month, 3-month, 6-month, and 1-year post-stroke follow-ups (adjusted hazard ratios = 0.84, 0.90, 0.88, and 0.92, respectively); additionally, this approach significantly decreased mortality risk at each post-stroke follow-up period (p < 0.05).</p><p><strong>Conclusions: </strong>BGM combined with glycemic treatment significantly improves prognosis in patients with FISHG who have not been previously diagnosed with DM, reducing the risks of stroke recurrence and mortality.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"302"},"PeriodicalIF":3.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657440/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Structural validity of the Brazilian version of the quality care questionnaire-palliative care for use in individuals with diabetes mellitus eligible for palliative care.","authors":"Abraão Albino Mendes-Júnior, Aldair Darlan Santos-de-Araújo, Leonel Richard de Oliveira Silva Santos, Lorena Lúcia Costa Ladeira, Meire Coelho Ferreira, Louise Aline Romão Godim, Mariana Campos Maia, Marinete Rodrigues de Farias Diniz, Almir Vieira Dibai-Filho, Daniela Bassi-Dibai","doi":"10.1186/s13098-024-01548-w","DOIUrl":"10.1186/s13098-024-01548-w","url":null,"abstract":"<p><strong>Background: </strong>The Brazilian version of the Quality Care Questionnaire-Palliative Care (QCQ-PC) is an instrument designed to assess the quality of care provided in palliative care from the user's perspective, featuring easy comprehension and applicability. It has demonstrated validity for use in individuals with cancer, but there is a need for validation in other populations due to the scarcity of instruments with this purpose.</p><p><strong>Objective: </strong>To structurally validate the Brazilian version of the QCQ-PC for use in individuals with diabetes mellitus (DM) eligible for palliative care.</p><p><strong>Methods: </strong>This is a structural validation study of a questionnaire according to the Consensus-based Standards for the Selection of Health Measurement Instruments (COSMIN). The study was conducted with 100 individuals with DM. Data collection occurred in differents care services in São Luís (northeast Brazil) by means of the application of the QCQ-PC and a form with sociodemographic, clinical, and daily habit data. Descriptive data analysis was performed using absolute values, relative frequencies, and measures of central tendency and dispersion. Structural validity was assessed by means of exploratory factor analysis (EFA).</p><p><strong>Results: </strong>Of the 100 participants included in the study, 66% were female, 54% were single, with a median age of 64 years, 44% were overweight (44%), 77% were on polypharmacy, and 70% were physically inactive. We found that one domain is the most appropriate for use of the QCQ-PC in individuals with DM eligible for palliative care, according to the parallel analysis implemented in the EFA. This domain was named \"quality of care\". The fit indices for this one-dimensional internal structure were adequate: Kaiser-Meyer-Olkin test = 0.71, p value < 0.01 in Bartlett's test, chi-square/degree of freedom = 1.07, comparative fit index = 0.993, Tucker-Lewis index. = 0.991, root mean square error of approximation = 0.028. The QCQ-PC presented factor loadings ranging from 0.480 to 0.883, maintaining a total of 12 items, which demonstrates the adequate relationship between the quality of care domain and its items.</p><p><strong>Conclusion: </strong>Therefore, the internal structure with one domain (quality of care) is the most suitable for use in individuals with DM eligible for palliative care by means of the QCQ-PC.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"306"},"PeriodicalIF":3.4,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657213/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853400","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular volume changes in radiological patterns of usual interstitial pneumonia in patients with type 2 diabetes.","authors":"Jiarong Wang, Yuanchao Li, Hao Chen, Jianbo Wang","doi":"10.1186/s13098-024-01551-1","DOIUrl":"10.1186/s13098-024-01551-1","url":null,"abstract":"<p><strong>Objective: </strong>This research primarily focuses on exploring the changes in intrapulmonary vascular volume (IPVV) in radiological patterns of usual interstitial pneumonia (UIP) associated with Type 2 Diabetes Mellitus (T2DM), thereby inferring the possible mechanisms of the co-occurrence of diabetes and UIP patterns.</p><p><strong>Methods: </strong>Thin-layer data were post-processed on the basis of high-resolution computed tomography (HRCT) and quantitatively assessed for IPVV. Changes in IPVV were compared between T2DM combined with UIP modality and T2DM non-UIP modality. Correlations between UIP patterns and various markers and confounders, including IPVV, were determined via logistic regression analysis. In this study, the potential of IPVV as a predictor for UIP presence was analysed through the application of subject operating characteristic curve analysis.</p><p><strong>Results: </strong>In patients with T2DM, the IPVV demonstrated smaller size in those with combined UIP patterns compared to T2DM patients without UIP patterns (164.4 ± 68.7 vs 202.9 ± 76.3 mL, P = 0.005). We detected a positive correlation between IPVV levels and several variables, including fasting plasma glucose (FPG) (r = 0.404, P < 0.0001), glycated hemoglobin (HbA1c) (r = 0.225, P = 0.022), serum uric acid (SUA) (r = 0.332, P = 0.0007) and HRCT scores (r = 0.288, P = 0.024). Conversely, negative correlations were noted with total cholesterol (TC) (r = -0.220, P = 0.028) and cystatin-C (Cys-C) (r = -0.215, P = 0.038). Multivariate logistic regression analysis identified independent associations between the presence of UIP and several factors: IPVV, age, smoking history, and FPG. In assessing the combined UIP pattern among T2DM patients, IPVV levels exhibited a sensitivity of 70.5% and a specificity of 58.5%, generating an AUC of 0.645.</p><p><strong>Conclusion: </strong>In individuals diagnosed with T2DM alongside UIP, a substantial decline in IPVV was documented. This diminution correlates with the presence of UIP, suggesting that IPVV may serve as a potent biomarker for detecting UIP patterns in individuals with T2DM. This may suggest that the mechanism behind the co-occurrence of T2DM with UIP patterns is attributed to alterations in the pulmonary microvasculature, potentially representing one of the vascular complications associated with diabetes.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"298"},"PeriodicalIF":3.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657450/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of SGLT2 inhibitors on cardiovascular outcomes and metabolic events in Chinese han patients with chronic heart failure.","authors":"Fei Li, Rewaan Baheti, Mengying Jin, Wei Xiong, Jiawei Duan, Peng Fang, Jing Wan","doi":"10.1186/s13098-024-01553-z","DOIUrl":"10.1186/s13098-024-01553-z","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the real-world impact of sodium-glucose cotransporter 2 inhibitors (SGLT2i) on the efficacy, safety, and metabolic profiles of patients with chronic heart failure (CHF), both with and without type 2 diabetes mellitus (T2DM).</p><p><strong>Methods: </strong>A cohort of 1,130 patients with reduced ejection fraction chronic heart failure (HFrEF) was recruited from Zhongnan Hospital of Wuhan University, spanning January 2021 to August 2023. Among these, 154 patients received SGLT2i therapy, while 131 patients were assigned to a non-SGLT2i group, following specified inclusion and exclusion criteria. The association between SGLT2i therapy and the risk of primary and secondary endpoints was analyzed, alongside the effect of guideline-recommended heart failure medications at varying dosages on Major Adverse Cardiovascular Events (MACE).</p><p><strong>Results: </strong>SGLT2i treatment led to reductions in blood pressure, uric acid, NT-proBNP, and pulmonary artery pressure, while increasing body mass index (BMI) and left ventricular ejection fraction (LVEF) in CHF patients. Multivariate Cox regression analysis revealed that SGLT2i therapy reduced the primary endpoint risk by 40.3% (HR 0.597, 95% CI 0.356-0.973, p = 0.047). Univariate Cox regression indicated that SGLT2i might also reduce the incidence of new diagnoses of atrial fibrillation, non-fatal acute myocardial infarction, and MACE in CHF patients. Moreover, the use of a four-drug combination for heart failure management was associated with a lower risk of MACE compared to monotherapy.</p><p><strong>Conclusion: </strong>SGLT2i therapy not only enhances LVEF but also significantly reduces ambulatory blood pressure, uric acid, fasting blood glucose, pulmonary artery pressure, and NT-proBNP levels in CHF patients. Additionally, SGLT2i improves prognosis by lowering the risk of both primary and secondary endpoints. Compared to monotherapy, a four-drug regimen for CHF substantially reduces the risk of MACE, supporting the effectiveness of comprehensive treatment strategies.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"299"},"PeriodicalIF":3.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657645/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between metabolic syndrome and the risk of glaucoma: a meta-analysis of observational studies.","authors":"Fei Li, Yanjun Luo, Xin Li, Yan Dai, Qingping Xiang","doi":"10.1186/s13098-024-01532-4","DOIUrl":"10.1186/s13098-024-01532-4","url":null,"abstract":"<p><strong>Background: </strong>The potential link between metabolic syndrome (MetS) and the risk of glaucoma has been proposed but remains inconclusive. This meta-analysis aimed to systematically evaluate the association between MetS and the risk of glaucoma.</p><p><strong>Methods: </strong>We conducted a comprehensive search of PubMed, Embase, and Web of Science from inception to August 12, 2024, for observational studies assessing the relationship between MetS and glaucoma risk. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated to estimate the association. Heterogeneity was assessed using I² statistics, and a random-effects model was applied.</p><p><strong>Results: </strong>Nine studies involving 2,258,797 participants were included. The pooled results showed that MetS was significantly associated with an increased risk of glaucoma (OR: 1.34, 95% CI 1.15-1.55, p < 0.001; I² = 75%). Subgroup analyses according to the individual component of MetS suggested that hypertension and hyperglycemia were significantly associated with glaucoma, but not for obesity or dyslipidemia, although the difference among subgroups was not significant (p = 0.05). Further subgroup and meta-regression analyses suggested that the results were not significantly affected by study design, average age, sex, method of glaucoma diagnosis, or glaucoma subtype (primary open-angle glaucoma or normal-tension glaucoma). Sensitivity analysis confirmed the robustness of the findings.</p><p><strong>Conclusions: </strong>This meta-analysis suggests that MetS is significantly associated with an increased risk of glaucoma. These findings highlight the need for heightened awareness and potential screening strategies for glaucoma in individuals with MetS. Further studies are required to elucidate underlying mechanisms and causality.</p>","PeriodicalId":11106,"journal":{"name":"Diabetology & Metabolic Syndrome","volume":"16 1","pages":"300"},"PeriodicalIF":3.4,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657432/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142853209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}